skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

1094 Total results for product and free and sample content found

Datamonitor Healthcare

Better Heart Health Whitepaper

22 Oct 2018

In recognition of World Heart Day, September 29, 2018, Informa Pharma Intelligence would like to invite you to download our latest whitepaper, Better Heart Health with Mobile Apps? The Impact of Mobile Apps on Coronary Heart Disease in the US. This exploration into the results of a recent analysis of the US Behavioral Risk Factor Surveillance System (BRFSS), coupled with an analysis of several health apps targeting coronary heart disease (CHD) and other heart disease factors, is available to you now – for free.


Biomedtracker Q4 2018 Outlook Report

19 Oct 2018

Find out what’s in store for the remainder of 2018 with your copy of the Biomedtracker Q4 2018 Outlook Report Extract. This essential analysis of expected Q4 catalysts for 27 drugs is now available to you – for free. Drawn from the full report of the same name, this vital resource explores the likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) based on a drug’s phase, drug class, and disease group.

Topic Drug development landscape


2017 Completed Trials

By Christine Blazynski, PhD 19 Oct 2018

As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.

Topic Clinical trials

Citeline, Trialtrove

Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

By Laura Runkel 19 Oct 2018

Explore the current and future outlook for rheumatoid arthritis (RA) treatments. Such treatments remain ineffective for the 33% of RA sufferers who are or become unresponsive to treatment, resulting in a high interest in RA drug development to address this unmet need in the marketplace.

Medtech Insight

Proposed 510(k) Changes Elicit Some Industry Skepticism

By Elizabeth Orr 18 Oct 2018

Two 510(k) pilots from US FDA indicate the agency's desire for faster, easier clearances. But some observers aren’t sure if they’ll lead to real improvements.

Topic FDA

Pink Sheet

DTC Advertising: The 'Kick Me' Sign On Big Pharma's Backs

By Michael McCaughan 18 Oct 2018

Treating mandatory wholesale acquisition cost disclosure in TV ads as a major drug pricing reform is close to ludicrous. But the broad approval of the action is an important sign of the continued public image cost of the ads to the drug companies.

Topic Drug approval Drug review

Pink Sheet

Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars

By Ian Schofield 18 Oct 2018

Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.

Topic Business strategies Company analysis

Medtech Insight

US FDA Shelves Proposal To Mandate Home-Use Device E-Labeling

By David Filmore 18 Oct 2018

A controversial 2016 proposed rule that would have required manufacturers of many class II and class III home-use devices to electronically submit device labeling information to US FDA will not be finalized, the agency affirmed in the Oct. 17 HHS Unified Agenda document. The agency also signaled plans to imminently finalize a broad device classification rule, and other updates.

Topic Medtech


Industry Makes A Drug Price Transparency Push In DTC Ads, But Is It Too Little Too Late?

By Jessica Merrill 18 Oct 2018

PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads.

Topic Drug approval Drug review

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: